Related Experiment Video
Updated: Aug 11, 2026
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Rifampicin attenuates the MPTP-induced neurotoxicity in mouse brain
Y Oida1, K Kitaichi, H Nakayama
1Department of Biofunctional Molecules, Gifu Pharmaceutical University, 5-6-1 Mitahora-higashi, Gifu 502-8585, Japan.
Abstract:
Rifampicin, an antibacterial drug, is highly effective in the treatment of tuberculosis and leprosy. Recently, it has been reported to have neuroprotective effects in in vitro and in vivo models. This study was designed to elucidate its neuroprotective effects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity (known as an in vivo mouse model of Parkinson's disease). Mice were injected intraperitoneally (i.p.) with MPTP (10 mg/kg) four times at 1-h intervals, and brains were analyzed 3 or 7 days later. Rifampicin at 20 mg/kg (i.p., twice) had protective effects against MPTP-induced neuronal damage (immunohistochemical changes in tyrosine hydroxylase) in both the substantia nigra and striatum. Rifampicin also protected against the MPTP-induced depletions of dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) in the striatum. The maximal concentrations of rifampicin between 30 and 240 min after a single rifampicin injection (20 mg/kg, i.p.) were 2.6 microM (at 30 min) in plasma and 0.77 microM (at 60 min) in striatum. Next, the effects of rifampicin on oxidative stress [lipid peroxidation in mouse brain homogenates and free radical-scavenging activity against diphenyl-p-picrylhydrazyl (DPPH)] were evaluated to clarify the underlying mechanism. At 1 microM or more, rifampicin significantly inhibited both lipid peroxidation in the striatum and free radical production. These findings suggest that in mice, rifampicin can reach brain tissues at concentrations sufficient to attenuate MPTP-induced neurodegeneration in the nigrostriatal dopaminergic neuronal pathway, and that an inhibitory effect against oxidative stress may be partly responsible for its observed neuroprotective effects.
Insights
Rifampicin demonstrates neuroprotective effects by reducing neuronal damage and restoring dopamine levels in a mouse model of Parkinson's disease. This action is linked to its ability to combat oxidative stress in the brain.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Rifampicin, an antibiotic for tuberculosis and leprosy, shows potential neuroprotective properties.
- Parkinson's disease is characterized by the degeneration of dopaminergic neurons.
- 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin used to model Parkinson's disease in vivo.
Purpose of the Study:
- To investigate the neuroprotective effects of rifampicin against MPTP-induced neurotoxicity in a mouse model.
- To determine if rifampicin can prevent neuronal damage and dopamine depletion in the nigrostriatal pathway.
- To explore the role of oxidative stress in rifampicin's neuroprotective mechanism.
Main Methods:
- Mice were administered MPTP to induce Parkinsonian-like symptoms.
- Rifampicin treatment was administered to assess its protective effects.
- Immunohistochemistry was used to evaluate neuronal damage (tyrosine hydroxylase).
- Neurotransmitter levels (dopamine, DOPAC, HVA) were measured in the striatum.
- In vitro assays assessed lipid peroxidation and free radical scavenging activity.
Main Results:
- Rifampicin (20 mg/kg) significantly protected against MPTP-induced neuronal damage in the substantia nigra and striatum.
- Rifampicin prevented the depletion of dopamine and its metabolites (DOPAC, HVA) in the striatum.
- Rifampicin reached effective concentrations in both plasma and striatum.
- Rifampicin inhibited lipid peroxidation and scavenged free radicals in brain homogenates.
Conclusions:
- Rifampicin exhibits significant neuroprotective effects in an MPTP-induced mouse model of Parkinson's disease.
- The neuroprotection is associated with the drug's ability to reach brain tissue and counteract oxidative stress.
- Rifampicin's mechanism may involve mitigating oxidative damage in the nigrostriatal dopaminergic pathway.
